Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-31

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of intravenous dexmedetomidine versus dexamethasone for management of repound pain after supraclavicular brachial plexus block.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perineural Dexamethasone, Dexmedetomidine, or Their Combination to Reduces Rebound Pain After Supraclavicular Brachial Plexus Block

NCT07299877

Brachial Plexus Blocks

NOT_YET_RECRUITING PHASE4

Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block

NCT03385967

Analgesia Pain, Acute Peripheral Nerve Block

WITHDRAWN PHASE4

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

NCT07290595

Post Operative Analgesia Bradycardia Hypotension +1 more

RECRUITING PHASE2/PHASE3

the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block

NCT02961361

Injury of Upper Limb

COMPLETED PHASE4

Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery

NCT04394481

Analgesia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trauma Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine group will receive 0.5 mcg/kg

Group Type EXPERIMENTAL

Dexmedetomidine injection

Intervention Type DRUG

Dexmedetomidine group will receive 0.5 mcg/kg

Dexamethasone group will receive 8mg/kg

Group Type EXPERIMENTAL

Dexmedetomidine injection

Intervention Type DRUG

Dexmedetomidine group will receive 0.5 mcg/kg

Control group will receive equivalent volume of saline 0.9%.

Group Type EXPERIMENTAL

Dexmedetomidine injection

Intervention Type DRUG

Dexmedetomidine group will receive 0.5 mcg/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine injection

Dexmedetomidine group will receive 0.5 mcg/kg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexamethasone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 20\_60 years old

* Patients with ASA clinical status I/II
* Patients scheduled for peripheral nerve block for upper extremity surgery

Exclusion Criteria

* 1\) they refused to participate 2) had preexisting neuropathy of the surgical limb 3) hypersensitivity to amide anesthetic 4) significant pulmonary disease 5) coagulopathy 6) sepsis 7) infection at the block site 8) hypersensitivity to dexmedetomidine \& dexamethasone

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes